Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism

CPT: Pharmacometrics and Systems Pharmacology

Volumn 3, Issue 11, 2014, Pages

  Madrasi, K ^a   Burns, R N ^a   Hendrix, C W ^b   Fossler, M J ^c   Chaturvedula, A ^a  

^a MERCER UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; DRUG METABOLITE; HUMAN ADENYLATE KINASE 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; TENOFOVIR; UNCLASSIFIED DRUG;

ARTICLE; CELL METABOLISM; CELL TRANSPORT; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG UPTAKE; ENZYME KINETICS; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MICHAELIS CONSTANT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STEADY STATE;

EID: 84927759470     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2014.46     Document Type: Article

References (37)

1. Anderson, P.L., Kiser, J.J., Gardner, E.M., Rower, J.E., Meditz, A. & Grant, R.M. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J. Antimicrob. Chemother. 66, 240-250 (2011).
2. Kearney, B.P., Flaherty, J.F. & Shah, J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin. Pharmacokinet. 43, 595-612 (2004).
3. Naesens, L., Balzarini, J., Bischofberger, N. & De Clercq, E. Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl) adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl) adenine. Antimicrob. Agents Chemother. 40, 22-28 (1996).
4. von Kleist, M., Metzner, P., Marquet, R. & Schütte, C. HIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selection. PLoS Comput. Biol. 8, e1002359 (2012).
5. Dixit, N.M. & Perelson, A.S. Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay. J. Theor. Biol. 226, 95-109 (2004).
6. Duwal, S., Schütte, C. & von Kleist, M. Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection. PLoS One 7, e40382 (2012).
7. Blum, M.R., Chittick, G.E., Begley, J.A. & Zong, J. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J. Clin. Pharmacol. 47, 751-759 (2007).
8. Chittick, G.E. et al. Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state. Antimicrob. Agents Chemother. 50, 1304-1310 (2006).
9. Droste, J.A. et al. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. Antimicrob. Agents Chemother. 49, 680-684 (2005).
10. Jullien, V. et al. Population pharmacokinetics of tenofovir in human immunodeficiency virusinfected patients taking highly active antiretroviral therapy. Antimicrob. Agents Chemother. 49, 3361-3366 (2005).
11. Baheti, G., Kiser, J.J., Havens, P.L. & Fletcher, C.V. Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients. Antimicrob. Agents Chemother. 55, 5294-5299 (2011).
12. Barditch-Crovo, P. et al. Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 45, 2733-2739 (2001).
13. Hawkins, T., Veikley, W., St Claire, R.L. 3rd, Guyer, B., Clark, N. & Kearney, B.P. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J. Acquir. Immune Defic. Syndr. 39, 406-411 (2005).
14. von Kleist, M. & Huisinga, W. Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to viral escape: an example based on zidovudine. Eur. J. Pharm. Sci. 36, 532-543 (2009).
15. Huxley, J.S. Problems of Relative Growth. BiblioBazaar, 2011.
16. Snell, O. Die Abhängigkeit des Hirngewichtes von dem Körpergewicht und den geistigen Fähigkeiten. Archiv für Psychiatrie und Nervenkrankheiten 23, 436-446 (1892).
17. Thompson, D.A.W. & Bonner, J.T. On Growth and Form. Cambridge University Press, New York, 1992.
18. European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on Strategies to Identify and Mitigate Risks for First-In-Human Clinical Trials With Investigational Medicinal Products. European Medicines Agency, London, 2007.
19. Lalonde, R.L. et al. Model-based drug development. Clin. Pharmacol. Ther. 82, 21-32 (2007).
20. Milligan, P.A. et al. Model-based drug development: a rational approach to efficiently accelerate drug development. Clin. Pharmacol. Ther. 93, 502-514 (2013).
21. Rostami-Hodjegan, A. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin. Pharmacol. Ther. 92, 50-61 (2012).
22. Zhao, P. et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin. Pharmacol. Ther. 89, 259-267 (2011).
23. Hendrix, C.W. et al. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One 8, e55013 (2013).
24. Gilead Sciences Inc. Clinical pharmacology and biopharmaceutics review of Viread. In: Research. (Food and Drug Administration, Washington, DC, 2001).
25. Choi, S.U., Bui, T. & Ho, R.J. pH-dependent interactions of indinavir and lipids in nanoparticles and their ability to entrap a solute. J. Pharm. Sci. 97, 931-943 (2008).
26. Louissaint, N.A. et al. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res. Hum. Retroviruses 29, 1443-1450 (2013).
27. Minnis, A.M. et al. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav. 17, 737-747 (2013).
28. Hawkins, T. et al. Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients. Antimicrob. Agents Chemother. 55, 1549-1555 (2011).
29. Hendrix, C.W. et al. Tenofovir-Emtricitabine Directly Observed Dosing: 100% Adherence Concentrations (HPTN 066). 21st Conference on Retroviruses and Opportunistic Infections, 3-6 March 2014, Boston, MA.
30. Liptrott, N.J., Curley, P., Moss, D., Back, D.J., Khoo, S.H. & Owen, A. Interactions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation. J. Antimicrob. Chemother. 68, 2545-2549 (2013).
31. Robbins, B.L., Srinivas, R.V., Kim, C., Bischofberger, N. & Fridland, A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob. Agents Chemother. 42, 612-617 (1998).
32. Urquhart, J. Role of patient compliance in clinical pharmacokinetics. A review of recent research. Clin. Pharmacokinet. 27, 202-215 (1994).
33. Kim, A.E., Dintaman, J.M., Waddell, D.S. & Silverman, J.A. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J. Pharmacol. Exp. Ther. 286, 1439-1445 (1998).
34. Owen, A. et al. In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. J. Pharmacol. Exp. Ther. 314, 1202-1209 (2005).
35. McKay, M.D., Beckman, R.J. & Conover, W.J. A comparison of three methods for selecting values of input variables in the analysis of output from a computer code. Technometrics 42, 55-61 (2000).
36. Bui, T.D., Dabdub, D. & George, S.C. Modeling bronchial circulation with application to soluble gas exchange: description and sensitivity analysis. J. Appl. Physiol. (1985). 84, 2070-2088 (1998).
37. Kapela, A., Bezerianos, A. & Tsoukias, N.M. A mathematical model of Ca2+ dynamics in rat mesenteric smooth muscle cell: agonist and NO stimulation. J. Theor. Biol. 253, 238-260 (2008).